Drugs / Bifidobacterium bifidum
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06719596 | May 2024 → Jun 2025 overdue | infectious disease | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06560879 | Feb → Dec 2025 overdue | digestive system disorder, precursor lymphoblastic lymphoma/leukemia | National Institute of Pediatrics, Mexico | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT03033199 | Jan 2017 → Feb 2018 | autoimmune thrombocytopenia | Shandong University | Unknown | No outcome recorded |
| Phase 2 | NCT02307383 | Oct 2014 → Oct 2015 | — | Instituto de Investigación Hospital Universitario La Paz | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05730777 | Feb → Jul 2023 | chemotherapy-induced toxicity | Peking University Third Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium bifidum | “probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one...” NCT03033199 ↗4“Eight long-term intestinal carriers of OXA-48-producing Enterobacteriaceae (OXA-PE) were treated during 3 weeks with daily oral lactitol (Emportal®), Bifidobacterium bifidum...” PMID 32280375 ↗ Apr 2020 |
| Known as | B. bifidum | “B. bifidum is an essential bacteria found in the human intestine.” NCT06560879 ↗ |
| Route | Oral | “orally intake either probiotic supplements” NCT03033199 ↗ |